Acumen Pharmaceuticals Analyst Ratings
Acumen Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/20/2023 | 88.93% | B of A Securities | → $14 | Reinstates | → Buy |
| 07/17/2023 | 75.44% | Cantor Fitzgerald | → $13 | Reiterates | Overweight → Overweight |
| 07/17/2023 | 102.43% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/18/2023 | 75.44% | Cantor Fitzgerald | → $13 | Initiates Coverage On | → Overweight |
| 03/28/2023 | 75.44% | Credit Suisse | $16 → $13 | Maintains | Outperform |
| 03/28/2023 | 102.43% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 02/02/2023 | 102.43% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 11/15/2022 | 115.92% | Credit Suisse | $17 → $16 | Maintains | Outperform |
| 10/05/2022 | 196.9% | BTIG | $15 → $22 | Maintains | Buy |
| 07/15/2022 | 102.43% | BTIG | → $15 | Initiates Coverage On | → Buy |
| 06/30/2022 | 102.43% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 03/29/2022 | 129.42% | Credit Suisse | $26 → $17 | Maintains | Outperform |
| 01/21/2022 | 88.93% | B of A Securities | $16 → $14 | Upgrades | Neutral → Buy |
| 07/26/2021 | 264.37% | UBS | → $27 | Initiates Coverage On | → Buy |
| 07/26/2021 | 169.91% | B of A Securities | → $20 | Initiates Coverage On | → Neutral |
| 07/26/2021 | 250.88% | Credit Suisse | → $26 | Initiates Coverage On | → Outperform |
| 07/26/2021 | 264.37% | Stifel | → $27 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/20/2023 | 88.93% | B of A 證券 | → 14 美元 | 恢復 | → 購買 |
| 07/17/2023 | 75.44% | 坎託·菲茨傑拉德 | → 13 美元 | 重申 | 超重 → 超重 |
| 07/17/2023 | 102.43% | HC Wainwright & Co. | → 15 美元 | 重申 | 購買 → 購買 |
| 05/18/2023 | 75.44% | 坎託·菲茨傑拉德 | → 13 美元 | 啓動覆蓋開啓 | → 超重 |
| 03/28/2023 | 75.44% | 瑞士信貸 | 16 美元 → 13 美元 | 維護 | 跑贏大盤 |
| 03/28/2023 | 102.43% | HC Wainwright & Co. | → 15 美元 | 重申 | → 購買 |
| 02/02/2023 | 102.43% | HC Wainwright & Co. | → 15 美元 | 重申 | → 購買 |
| 11/15/2022 | 115.92% | 瑞士信貸 | 17 美元 → 16 美元 | 維護 | 跑贏大盤 |
| 2022年5月10日 | 196.9% | BTIG | 15 美元 → 22 美元 | 維護 | 購買 |
| 07/15/2022 | 102.43% | BTIG | → 15 美元 | 啓動覆蓋開啓 | → 購買 |
| 06/30/2022 | 102.43% | HC Wainwright & Co. | → 15 美元 | 啓動覆蓋開啓 | → 購買 |
| 2022 年 3 月 29 日 | 129.42% | 瑞士信貸 | 26 美元 → 17 美元 | 維護 | 跑贏大盤 |
| 01/21/2022 | 88.93% | B of A 證券 | 16 美元 → 14 美元 | 升級 | 中性 → 買入 |
| 2021 年 7 月 26 日 | 264.37% | 瑞銀（UBS） | → 27 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 7 月 26 日 | 169.91% | B of A 證券 | → 20 美元 | 啓動覆蓋開啓 | → 中立 |
| 2021 年 7 月 26 日 | 250.88% | 瑞士信貸 | → 26 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2021 年 7 月 26 日 | 264.37% | Stifel | → 27 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Acumen Pharmaceuticals (ABOS)?
Acumen Pharmicals（ABOS）的目標價格是多少？
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by B of A Securities on July 20, 2023. The analyst firm set a price target for $14.00 expecting ABOS to rise to within 12 months (a possible 88.93% upside). 9 analyst firms have reported ratings in the last year.
A Securities於2023年7月20日公佈了Acumen Pharmicals（納斯達克股票代碼：ABOS）的最新目標股價。該分析公司將目標股價定爲14.00美元，預計ABOS將在12個月內升至12個月內（可能上漲88.93％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Acumen Pharmaceuticals (ABOS)?
分析師對Acumen Pharmicals（ABOS）的最新評級是多少？
The latest analyst rating for Acumen Pharmaceuticals (NASDAQ: ABOS) was provided by B of A Securities, and Acumen Pharmaceuticals their buy rating.
Acumen Pharmicals（納斯達克股票代碼：ABOS）的最新分析師評級由B of A Securities提供，Acumen Pharmicals提供買入評級。
When is the next analyst rating going to be posted or updated for Acumen Pharmaceuticals (ABOS)?
Acumen Pharmicals（ABOS）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on July 20, 2023 so you should expect the next rating to be made available sometime around July 20, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Acumen Pharmicals的高管和客戶交談以及聽取財報電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Acumen Pharmicals的最後一次評級是在2023年7月20日提交的，因此你應該預計下一個評級將在2024年7月20日左右公佈。
Is the Analyst Rating Acumen Pharmaceuticals (ABOS) correct?
分析師對Acumen Pharmicals（ABOS）的評級正確嗎？
While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a with a price target of $0.00 to $14.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $7.41, which is within the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的Acumen Pharmicals（ABOS）評級爲a，目標股價爲0.00美元至14.00美元。Acumen Pharmicals（ABOS）目前的交易價格爲7.41美元，在分析師的預測區間內。